A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

British Journal of Cancer

Volumn 96, Issue 1, 2007, Pages 29-37

  Benson, C ^a   White, J ^b   De Bono, J ^a   O'Donnell, A ^a   Raynaud, F ^a   Cruickshank, C ^c   McGrath, H ^d   Walton, M ^a   Workman, P ^a   Kaye, S ^a   Cassidy, J ^b   Gianella Borradori, A ^c   Judson, I ^a   Twelves, C ^e,f  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d CYCLACEL LTD   (United Kingdom)

^e BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^f UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Cyclin dependent kinase inhibitor; Phase I clinical trial

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; ROSCOVITINE;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HALF LIFE; FATIGUE; FEMALE; GLUCOSURIA; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; KIDNEY PERFUSION; KIDNEY TUBULE DISORDER; LETHARGY; LYMPHOCYTOPENIA; MALE; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RENOGRAPHY; SIDE EFFECT; SOLID TUMOR;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PURINES; TREATMENT OUTCOME;

EID: 33846254185     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603509     Document Type: Article

References (29)

1. Alvi AJ, Austen B, Weston VJ, Fegan C, MacCallum D, Gianella-Borradori A, Lane DP, Hubank M, Powell JE, Wei W, Taylor AMR, Moss PAH, Tatjana Stankovic T (2005) A novel Cdk inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 105: 4484-4491
2. Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B, Koken M, Coburn SP, Tang L, Jiang T, Liang DC, Galons H, Dierick JF, Pinna LA, Meggio F, Tozke F, Schachtele C, Lerman AS, Carno A, Wan Y, Gray N, Meijer L (2005) Roscovitine targets: protein kinase and pyridoxal kinase. J Biol Chem 280: 31208-31219
3. Benson B, Kaye S, Workman P, Garrett M, Walton M, de Bono J (2005) Clinical anticancer drug development: targeting the cyclin dependent kinase. Br J Cancer 92: 7-12
4. De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH (1997) Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 243: 518-526
5. De la Motte S, Gianella-Borradori A (2004) Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects. Int J Clin Pharmacol Ther 42: 232-239
6. Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L, Kim SH, Lockhart DJ, Schultz PG (1998) Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281: 533-538
7. Lu W, Chen L, Peng Y, Chen J (2001) Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 20: 3206-3216
8. MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, Lane DP, Green SR (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65: 5399-5407
9. Malumbres M, Barbacid M (2001) To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1: 222-231
10. Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, Ortega S, Dubus P, Barbacid M (2004) Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118: 493-504
11. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, Lane DP (2002) In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 102: 463-468
12. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243: 527-536
13. Meijer L, Raymond E (2003) Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 36: 417-425
14. Nutley BP, Raynaud FI, Wilson SC, Fischer PM, Hayes A, Goddard PM, McClue SJ, Jarman M, Lane DP, Workman P (2005) Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-Roscovitine in the mouse. Mol Cancer Ther 4: 125-139
15. Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R, Barbero JL, Malumbres M, Barbacid M (2003) Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 35: 25-31
16. Pierga J, Faivre S, Vera K, Laurence V, Delbaldo C, Bekradda M, Armand JP, Gianella-Borradori A, Dieras V, Raymond E (2003) A phase I and pharmacokinetic (PK) trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor, in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 22: Abstr. 210
17. Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H, Shiraishi N, Chauhan D, Munshi NC, Green SR, Anderson KC (2005) Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 106: 1042-1047
18. Raynaud FI, Fischer PM, Nutley BP, Goddard PM, Lane DP, Workman P (2004) Cassette dosing pharmacokinetics of a library of 2, 6, 9-trisubstituted purine cyclin-dependent kinase 2 inhibitors by parallel synthesis. Mol Cancer Ther 3: 353-362
19. Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE, Garrett MD, Rogers P, Clarke SJ, Kelland LR, Valenti M, Brunton L, Eccles S, Lane DP, Workman P (2005) In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 11: 4875-4887
20. Sausville EA (2002) Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 8(Suppl 4): S32-S37
21. Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM (2001) Phase I trial of 72-h continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19: 2319-2333
22. Schutte B, Nieland L, van Engeland M, Henfling ME, Meijer L, Ramaekers FC (1997) The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp Cell Res 236: 4-15
23. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16: 2986-2999
24. Tan AR, Yang X, Berman A, Zhai S, Sparreboom A, Parr AL, Chow C, Brahim JS, Steinberg SM, Figg WD, Swain SM (2004) Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res 10: 5038-5047
25. Tang L, Li MH, Cao P, Wang F, Chang WR, Bach S, Reinhardt J, Ferandin Y, Galons H, Wan Y, Gray N, Meijer L, Jiang T, Liang DC (2005) Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. J Biol Chem 280: 31220-31229
26. Tetsu O, McCormick F (2003) Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3: 233-245
27. Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnoch R, Dresen A, Wilding G (2002) Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 50: 465-472
28. Vita M, Abdel-Rehim M, Nilsson C, Hassan Z, Skansen P, Wan H, Meurling L, Hassan M (2005) Stability, pKa and plasma protein binding of roscovitine. J Chromatogr B Analyt Technol Biomed Life Sci 821: 75-80
29. Whittaker SR, Walton MI, Garrett MD, Workman P (2004) The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits RB phosphorylation, causes loss of cyclin D1 and activates the mitogen activated protein kinase pathway. Cancer Res 64: 262-272